Publications — Radcliffe Department of Medicine

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

An immunodominant NP105-113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease.

Peng Y. et al, (2022), Nat Immunol, 23, 50 - 61

Increasing LFA-1 Expression Enhances Immune Synapse Architecture and T Cell Receptor Signaling in Jurkat E6.1 Cells

Cassioli C. et al, (2021), Frontiers in Cell and Developmental Biology, 9

RNA-Seq analysis of early transcriptional responses to activation in the leukaemic Jurkat E6.1 T cell line

Felce SL. et al, (2021), Wellcome Open Research, 5, 42 - 42

RNA-Seq analysis of early transcriptional responses to activation in the leukaemic Jurkat E6.1 T cell line

Felce SL. et al, (2020), Wellcome Open Research, 5, 42 - 42

CRISPR/Cas9-Mediated Foxp1 Silencing Restores Immune Surveillance in an Immunocompetent A20 Lymphoma Model.

Felce SL. et al, (2020), Front Oncol, 10

Discovery of a Selective Inhibitor for the YEATS Domains of ENL/AF9.

Christott T. et al, (2019), SLAS Discov, 24, 133 - 141

Discovery of an MLLT1/3 YEATS Domain Chemical Probe.

Moustakim M. et al, (2018), Angew Chem Int Ed Engl, 57, 16302 - 16307

Target Identification Using Chemical Probes.

Moustakim M. et al, (2018), 610, 27 - 58

N-terminally truncated FOXP1 protein expression and alternate internal FOXP1 promoter usage in normal and malignant B cells.

Brown PJ. et al, (2016), Haematologica, 101, 861 - 871

FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.

Brown PJ. et al, (2016), Leukemia, 30, 605 - 616

Recombinant viral vaccines for cancer

Cawood R. et al, (2012), Trends in Molecular Medicine, 18, 564 - 574

MicroRNA controlled adenovirus mediates anti-cancer efficacy without affecting endogenous microRNA activity.

Cawood R. et al, (2011), PLoS One, 6

Include forthcoming?